Abstract
A notable feature of coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus (SARS-CoV-2), is the high emergence of pulmonary and extrapulmonary thrombosis observed in patients with severe disease. The incidence of venous thromboembolism (VTE) varies between 6 and 86% depending on the investigations performed, follow-up time documented, and thromboprophylactic regimens used; the prevalence ranges between 15 and 40%. These are important numbers, especially compared with the prevalence of VTE associated with non-COVID-19 diseases (5–30%) [1]. Thus, VTE is an important consideration in the management of patients hospitalized with COVID-19 [2].
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Waite AAC, Hamilton DO, Pizzi R, Ageno W, Welters ID. Hypercoagulopathy in severe COVID-19: implications for acute care. Thromb Haemost. 2020;120:1654–67.
Spyropoulos AC, Levy JH, Ageno W, Connors JM, Hunt BJ, Iba T, et al. Scientific and Standardization Committee Communication: clinical guidance on the diagnosis, prevention, and treatment of venous thromboembolism in hospitalized patients with COVID-19. J Thromb Haemost. 2020;18:1859–65.
Rahi MS, Jindal V, Reyes SP, Gunasekaran K, Gupta R, Jaiyesimi I. Hematologic disorders associated with COVID-19: a review. Ann Hematol. 2021;100:309–20.
Robba C, Battaglini D, Ball L, Valbusa A, Porto I, Della Bona R, et al. Coagulative disorders in critically ill COVID-19 patients with acute distress respiratory syndrome: a critical review. J Clin Med. 2021;10:140.
Kwaan HC. The central role of fibrinolytic response in trauma-induced coagulopathy: a hematologist’s perspective. Semin Thromb Hemost. 2020;46:116–24.
Mazilu L, Katsiki N, Nikolouzakis TK, Aslanidis MI, Lazopoulos G, Kouretas D, et al. Thrombosis and haemostasis challenges in COVID-19—therapeutic perspectives of heparin and tissue-type plasminogen activator and potential toxicological reactions—a mini review. Food Chem Toxicol. 2021;148:111974.
Tang N, Li D, Wang X, Sun Z. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. 2020;18:844–7.
Salabei JK, Fishman TJ, Asnake ZT, Ali A, Iyer UG. COVID-19 coagulopathy: current knowledge and guidelines on anticoagulation. Heart Lung. 2021;50:357–60.
Biembengut ÍV, de Souza TACB. Coagulation modifiers targeting SARS-CoV-2 main protease Mpro for COVID-19 treatment: an in silico approach. Mem Inst Oswaldo Cruz. 2020;115:e200179.
Page EM, Ariëns RAS. Mechanisms of thrombosis and cardiovascular complications in COVID-19. Thromb Res. 2021;200:1–8.
Zanza C, Racca F, Longhitano Y, Piccioni A, Franceschi F, Artico M, et al. Risk management and treatment of coagulation disorders related to COVID-19 infection. Int J Environ Res Public Health. 2021;18:1268.
Lachant DJ, Lachant NA, Kouides P, Rappaport S, Prasad P, White RJ. Chronic therapeutic anticoagulation is associated with decreased thrombotic complications in SARS-CoV-2 infection. J Thromb Haemost. 2020;18:2640–5.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2022 The Author(s), under exclusive license to Springer Nature Switzerland AG
About this chapter
Cite this chapter
Felix, N.S., Castro Faria Neto, H.C., Cruz, F.F. (2022). Coagulation and Haemostasis. In: Battaglini, D., Pelosi, P. (eds) COVID-19 Critical and Intensive Care Medicine Essentials. Springer, Cham. https://doi.org/10.1007/978-3-030-94992-1_25
Download citation
DOI: https://doi.org/10.1007/978-3-030-94992-1_25
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-94991-4
Online ISBN: 978-3-030-94992-1
eBook Packages: MedicineMedicine (R0)